PTEN and cancer: In approximately one-third of the tested drug–gene pairs (30/89), the drug response seemed influenced by the cancer diversity of mutations (ANOVA, p < 0.2, Supplementary Data 7), such as temsirolimus-BRAF (ANOVA, p = 0.005), afatinib-EGFR (ANOVA, p = 2.92 × 10−8), gemcitabine-KRAS (ANOVA, p = 0.0009), and AZD6482-PTEN (ANOVA, p = 0.118) (Fig. 3b).